News
Pfizer beats Q2 estimates with rising oncology sales, new drug launches, and strong Seagen-driven portfolio growth.
Novo Nordisk's steep stock decline has pushed it into deep undervaluation, now trading at attractive multiples below ...
Shares of Novo Nordisk are trading lower Wednesday morning. The stock is extending a dramatic sell-off from Tuesday's session ...
Novo Nordisk shares plunged over 20% on Tuesday after the company named a new CEO and lowered its profit expectations, citing weaker sales of its popular weight-loss drug Wegovy due to competition ...
Shares in Novo Nordisk NOVO.B -2.27% plunged after it cut its guidance, a result from the company losing its lead in the booming market for weight-loss drugs, opening the door to competitors ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results